Navigation Links
Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
Date:5/22/2012

CAMBRIDGE, Mass. (May 22, 2012) Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

Researchers have theorized that inhibiting HSP90 just might render breast cancer cells less likely to escape the challenge posed by cutting off their ability to use estrogen. Such is the rationale for a new clinical trial that has begun enrolling patients this week.

In the trial, patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer will be treated either with fulvestrant, a drug currently marketed by AstraZeneca as Faslodex, or with a combination of fulvestrant and ganetespib, a drug which inhibits HSP90 and is now in clinical development by Synta Pharmaceuticals.

The trial's principal investigator is Nancy Lin, the Clinical Director of the Breast Oncology Center at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School. Lin is collaborating with Luke Whitesell, an oncologist and senior research scientist in the lab of Whitehead Institute Member Susan Lindquist.

Breast cancer is the most common cause of cancer-related deaths in women worldwide. An estimated 40,000 women in the United States are expected to die from the disease this year. In the developed world, approximately two-thirds of all breast cancer cases are ER+. Highly dependent on their estrogen receptors for growth and survival, these tumor cells are sensitive to hormonal therapies, making drugs like tamoxifen and fulvestrant effective first-line therapies for many patients.

However, in patients with breast cancers that recur or metastasize after initial hormonal
'/>"/>

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 CRN International has ... Services Operation. , Christina Upton, an 11-year veteran at ... Client Services responsible for managing the day-to-day execution of ... at the center of all activities for CRN clients, ... in the world . The department interfaces directly with ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent ... Chiropractic Association (FCA) National Convention and Expo, speaking on ... Chain Changes on Thursday, August 20th at the Hyatt ... the positive impact functional foot orthotics, like Foot Levelers ... pain, plantar fasciitis, and hammertoes. , Invented by a ...
(Date:7/29/2014)... Healthcare staffing agency Medical Solutions ... Tomorrow Scholarship Competition winners:, ,     Alonso ...     Racheal D., Freshman, Cerritos College in Norwalk, ... College in Houston, TX , Each ... hosts the Nurses of Tomorrow Scholarship competition as ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... 1WorldSync announces B. Braun Melsungen ... will utilize the Global Data Synchronization Network™ (GDSN®) ... share product information with the U.S. Food and ... their global supply chain. Holger Clobes, Head of ... "B. Braun serves customers in 61 countries, among ...
Breaking Medicine News(10 mins):Health News:CRN International Names New Director to Lead Client Services Department 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... recommendations for the diagnosis and subsequent treatment of superior ... the New England Journal of Medicine. ,The ... vena cava syndrome, provides clinical management evidence, and presents ... Lynn D. Wilson, M.D., MPH, Professor, Clinical Director, and ...
... need medical care in Korea but can afford it ... health services, according to a Yale School of ... Health. ,Low-income individuals with multiple chronic ... restrictions because they need and use more services, said ...
... to create therapies or simply investigate how organisms develop, ... of biological science's toughest assignments: keeping their tiny research ... notoriously finicky tastes, and despite a decade of advances, ... cells will continue dividing indefinitely in culture or begin ...
... needed to determine the true effects of low to ... impact on pregnant women of different policies on ... ,Recommendations for safe levels of drinking during ... organisations in Australia, according to new report written by ...
... of yoghurt could contain the cure for certain types ... . ,Overuse of antibiotics has led ... vancomycin-resistant enterococci (VRE), which are responsible for persistent and ... commercial yoghurts, may have a beneficial effect on human ...
... deceased older donors on a pump as opposed to ... cooler may lower hospital costs, improve initial organ ... according to new research by Wake Forest University Baptist Medical ... preservation times can be safely extended to permit more time ...
Cached Medicine News:Health News:Clinical Approach Defined for Superior Vena Cava Syndrome 2Health News:Poor and Chronically Ill in Korea Pay More for Healthcare 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 2Health News:New Technique Dissects Stem Cells' Picky Likes, Dislikes 3Health News:Better Research Needed On Alcohol In Pregnancy 2Health News:Preserving Kidneys on a Pump May Promote More Organ Sharing 2
(Date:7/29/2014)... , July 29, 2014 Research ... "Global Respiratory Devices Market 2014-2018" report to ... A respiratory device is a medical device ... is having difficulty in breathing and cannot achieve adequate ... such as cystic fibrosis, asthma, COPD, and ARDS require ...
(Date:7/29/2014)... Ill. , July 29, 2014  Sysmex America, ... and information systems technology, will feature an exhibit booth ... Annual Meeting and Clinical Lab Expo in ... 2014. "We are extremely excited to ... opportunity to interact with our customers and continue the ...
(Date:7/29/2014)... Calif. , July 29, 2014  Based ... response systems (PERS) market, Frost & Sullivan recognizes ... Sullivan Award for Price Performance Value Leadership. MobileHelp,s ... directly captures expectations for tech progression in personal ... consumers for these solutions. MobileHelp is ...
Breaking Medicine Technology:Global Respiratory Devices Market 2014-2018 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... America, Inc. (SAI), a leading medical diagnostic instrument ... Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: ... for Sysmex America, Inc. to provide fully automated ... of the systems has been completed.   ...
... Medical Systems (NYSE: VAR ) will hold an ... of  the American Society for Therapeutic Radiology and Oncology (ASTRO) ... are invited to join senior management for a review of ... at ASTRO. Varian will host a meeting with ...
Cached Medicine Technology:Sysmex America Announces LabCorp Hematology Automation Agreement 2Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010 2
100L...
... A fixed pipette is ideal ... single volume. Fixed volume FInnpipettes ... advantages as other Finnpipette Digital ... Super blow-out (1-40ul), Soft-touch tip ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: